A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Females must be of childbearing potential
Males must agree to use contraception
Have body mass index (BMI) between 18.0 and 32.0 kilogram/square meter (kg/m²), inclusive, and a body weight of greater than or equal to 50 kg.
In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clincial laboratory evaluations (congentical nonhemolytic hyperbilirubinemia) at screening and check-in, and from the physical examination at check-in as assessed by the investigator.
You may not be if
Have a 12-lead ECG abnormality that, in the opinion of the investigator,
* increases the risks associated with participating in the study
* may confound ECG data analysis
* a QTCF \>450 msec for males, or \>470 msec for females
* short PR interval \<120 msec or PR interval \>220 msec
* second or third degree atrioventricular block
* intraventricular conduction delay with QRS \>120 msec
* complete right bundle branch block
* left bundle branch block, or
* Wolff Parkinson-White syndrome.
Have had current or recent acute infection
Show evidence of active or latent tuberculosis (TB)
Had any surgical procedures within 12 weeks prior to screening or any planned surgical procedure scheduled to occur during the study.
Have a history or presence of multiple or severe allergies, or an anaphylactic reaction to prescription or non prescription drugs.
Are immunocompromised
Presence of active suicidal ideation or positive suicide behavior using baseline/screening version of the C-SSRS
Clareo Health | A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
